ScholarWorks@Korea University College of Medicine: Lee, Sung Yong

Detailed Information

Lee, Sung Yong (이승룡)

Guro Hospital (Department of Pulmonary, Allergy, and Critical Care Medicine, Guro Hospital)

Research Area: 종양면역, 폐암, Tumor Immunology, Lung Cancer

Tel 82-2-2626-3030
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Nonsmall cell lung cancer:10||lung cancer:7||nonsmall cell lung cancer:6||Chemotherapy:6||Afatinib:5||COPD:5||Lung cancer:5||exacerbation:4||EGFR:4||epidermal growth factor receptor:4||afatinib:4||Asthma:4||Nonsmallcell lung carcinoma:4||Biomarker:3||Reactive oxygen species:3||EGFR mutation:3||Osimertinib:3||nonsmall cell lung cancer (NSCLC):3||Acute lung injury:3||Chronic obstructive pulmonary disease:3||cellfree DNA:3||Carcinoma:3||nonsmallcell lung cancer:3||smoking:3||epidemiology:3||Korea:3||asthma:3||Lung neoplasms:3||realworld:3||Gefitinib:2||Epidermal growth factor receptor:2||chemotherapy:2||squamous cell carcinoma:2||Chemoradiotherapy:2||chronic obstructive pulmonary disease:2||Immune checkpoint inhibitor:2||tobacco smoke:2||tuberculosis:2||Guideline:2||cisplatin:2||whole exome sequencing:2||combined pulmonary fibrosis and emphysema:2||Chronic bronchitis:2||crizotinib:2||Biomarkers:2||Inflammation:2||NSCLC:2||Pleural effusion:2||Pneumonia:2||Cisplatin:2||epidermal growth factor receptor (EGFR):2||nonsmallcell lung carcinoma:2||osimertinib:2||firstline:2||gefitinib:2||Histone deacetylase inhibitor:2||Procalcitonin:2||Prognosis:2||Programmed cell death 1:2||prognosis:2||Human papillomavirus:2||immune tolerance:2||Small cell lung carcinoma:2||Smoking:2||inflammation:2||Cryotherapy:2||Surgery:2||biomarker:2||Survival:2||regulatory T cell:2||Bronchiectasis:2||T790M:2||Oxidative stress:2||Firstline:1||Firstline chemotherapy:1||Fluorouracil:1||Foxp3:1||Fungi:1||GAP score:1||GOLD:1||GRP78:1||Gemcitabine:1||Golytely:1||HPV:1||HPV16:1||Health:1||Health surveys:1||Heat shock protein:1||Hederacoside C:1||High resolution metabolomics:1||HighFlow Nasal Cannula:1||Histone deacetylase:1||Hospital mortality:1||Host immunity:1||Hydrogen sulfide:1||Hydromorphone:1||Hyponatremia:1||Ikappa B kinase inhibitor:1||IDO:1||Idiopathic pulmonary fibrosis:1||IgE:1||Immune checkpoint inhibitors:1||Immunoglobulin G:1||Implantable venous access port:1||Inappropriate ADH syndrome:1||Inhalation exposure:1||Insurance:1||Interleukin:1||Interleukin4:1||Interstitial:1||Lproline:1||LCMS:1||Leucovorin:1||Leukotriene:1||Leukotriene antagonist:1||Limbic encephalitis:1||Limitedstage:1||Lipid:1||Lipopolysaccharide:1||Lipopolysaccharides:1||Longterm home oxygen therapy:1||Lung Neoplasms:1||Lung adenocarcinoma:1||Lung diseases:1||Magnetic Resonance Imaging:1||Mediastinal neoplasms:1||Metabolomics:1||Mortality:1||Mucolytic agent:1||Mulberry:1||Neoadjuvant therapy:1||Nitric acid:1||NonSmallCell Lung:1||Nonsmall cell lung carcinoma:1||Nonsmallcell lung cancer:1||Noninvasive screening:1||Not available:1||Nuclear factor kappa B:1||Occupational exposure:1||Occupational lung disease:1||Oligodeoxynucleotides:1||Opioid:1||Oxaliplatin:1||PDL1:1||PGE(2):1||PNAmediated PCR clamping method:1||PPARgamma:1||PTEN:1||Paclitaxel:1||Paclitaxelloaded polymeric micelle:1||Pain:1||Paraneoplastic syndromes:1||Parapneumonic effusion:1||Peptide nucleic acids (PNAs):1||Phase III study:1||Plasma:1||Platinum:1||Pneumonitis:1||Polymorphism:1||Portal hypertension:1||Postprogression survival (PPS):1||Poverty:1||Predictive marker:1||Pregnancy:1||Primary biliary cirrhosis:1||Prognostic factor:1||Programmed death ligand 1:1||Promoter:1||Pseudomonas aeruginosa:1||Pulmonary adenocarcinoma:1||Pulmonary disease:1||Pulmonary edema:1||Pulmonary fibrosis:1||Pulmonary hypertension:1||Pulmonary nodules:1||Pulmonary reaction:1||Pulmonary rehabilitation:1||Pulmonary sarcomatoid carcinoma:1||Pulmonary surgical procedures:1||Quercetin:1||ROS1:1||Radiology:1||Raman spectrum:1||Realworld data:1||Realworld date:1||Realworld effectiveness:1||Realworld efficacy:1||Receptor:1||Registry:1||Reimbursement:1||Reintubation:1||Respiration:1||Respiration, Artificial:1||Respiratory Distress Syndrome, Adult:1||Respiratory function tests:1||Retinol:1||Risk factor:1||SAHA:1||Safety:1||Sarcoidosis:1||Serum:1||Singleincision technique:1||Skeletalrelated event:1||Small cell lung cancer:1||Specific model airway resistance:1||Squalene:1||Squamous Cell:1||Start of any treatment until the end of radiotherapy:1||Tlyrnphocytes:1||TAHPV:1||TKI:1||TNF alpha:1||TRALI:1||Teratoma pleural effusion:1||Therapeutic HPV vaccine:1||Therapeutics:1||Thorax:1||Thrombophlebitis:1||Thymidylate synthase:1||Transglutaminase 2:1||Trauma:1||Treatment Outcome:1||Treatment outcome:1||Tumor microenvironment:1||Tyrosine kinase inhibitor:1||Vaccine:1||Vaccinia virus:1||Vascular endothelial growth factor:1||VentilatorInduced Lung Injury:1||Ventilatorassociated event:1||Ventilatorassociated pneumonia:1||Ventilators:1||Vorinostat:1||Wild type:1||acquired resistance:1||acute exacerbation:1||acute exacerbation of COPD:1||adjuvant:1||adverse events:1||allergen:1||anaphylaxis:1||anaplastic lymphoma kinase:1||artificial:1||aspiration pneumonia:1||asthmalike symptoms:1||atezolizumab:1||bacterial infection:1||bacterium:1||blood tumor mutation burden:1||brain metastasis:1||brain metastasis (BM):1||cellfree DNA concentration:1||cerebellum metastasis:1||chemoradiotherapy:1||chest imaging:1||chronic obstructive pulmonary disease (COPD):1||circulating cellfree DNA (cfDNA):1||circulating tumor DNA:1||club cell secretory protein16:1||colorectal cancer:1||concurrent chemoradiation therapy:1||consolidation therapy:1||copy number alteration detection:1||deep learning:1||deterioration:1||drug allergy:1||drug resistance:1||economics:1||embolization:1||eosinophil:1||epidermal growth factor:1||epidermal growth factor receptor mutation:1||exosome:1||extracellular vesicles:1||food allergy:1||fungating mass:1||genomic profiling:1||haemangioma:1||highresolution CT:1||highresolution metabolomics:1||histamine release:1||histological type:1||immune checkpoint inhibitor:1||immune checkpoint inhibitor (ICI):1||immunotherapy:1||indoleamine2:1||interleukin (IL)6:1||interleukin10:1||interleukin27:1||irinotecan:1||lazertinib:1||levodropropizine:1||limited stage:1||lipopolysaccharide:1||liquid biopsy:1||liquid chromatographymass spectrometry:1||lung diseases:1||lung function:1||lung injury:1||malignant mesothelioma:1||manifestation:1||mechanical:1||mechanical ventilators:1||mediastinum:1||metabolic syndrome:1||metalloproteinase inhibitor:1||missense mutation:1||molecular profile:1||molecular targeted therapy:1||mortality:1||mucin:1||mucins:1||mucus hypersecretion:1||multiple sites:1||multiplex polymerase chain reaction:1||mutation:1||mutations:1||myositis:1||neoplasm staging:1||neutrophil:1||nextgeneration sequencing:1||non&#8208:1||nonsmall cell lung carcinoma:1||nonsmallcell carcinoma:1||nonsmallcell lung:1||obstructive lung disease:1||oncogene:1||outcome:1||pcDNA3CRT/E7:1||pembrolizumab:1||pemetrexed:1||phosphatase and tensin homolog deleted on chromosome 10:1||plasma cellfree DNA:1||plasma exchange:1||platinum:1||predictive biomarkers:1||predictors:1||prevalence:1||prognostic indicator:1||prognostic value:1||progressionfree survival:1||protein:1||proteomics:1||protooncogene proteins cakt:1||radiologicpathologic correlation:1||readmission:1||real world:1||realworld data:1||realworld efficacy:1||realworld study:1||rebamipide:1||rebiopsy:1||receptor, epidermal growth factor:1||rosiglitazone:1||rosigtitazone:1||screening:1||sequencing:1||single nucleotide polymorphism:1||small cell lung carcinoma:1||smallcell lung cancer:1||spirometry:1||statin:1||surfaceenhanced Raman spectroscopy:1||thymoma:1||transforming growth factorbeta:1||tyrosine kinase inhibitor (TKI):1||virus:1||viruses:1||분자생물학적 진단:1||비편평상피 폐암:1||상피세포성장인자 수용체:1||질산:1||1phosphatidylinositol 3kinase:1||화학성 폐렴:1||3bromopyruvate:1||3dioxygenase:1||ACO:1||ARDS:1||Acquired resistance:1||Acute Lung Injury:1||Adenocarcinoma:1||Adjuvant chemotherapy:1||Adjuvant therapy:1||Advanced lung cancer:1||Adverse events:1||Aged:1||Analgesics:1||Animal asthma model:1||Animal body plethysmography:1||AntiPD1:1||Antitumor:1||Apoptosis:1||Axillary vein:1||BAL:1||Bacteria:1||Bacterial:1||Belotecan:1||Berberine:1||Biologic markers:1||Bisphenol A:1||Blood transfusion:1||Bone metastases:1||Bortezomib:1||Bronchoalveolar lavage fluid:1||Bronchoscopy:1||CD8 T cells:1||CHOP:1||COX2:1||Cancer:1||Cancer vaccine:1||Carboplatin:1||Carcinoid tumor:1||Cardiac Dysfunction:1||Central airway obstruction:1||Cervical cancer:1||Chemical pneumonitis:1||Chronic obstructive:1||Chronic respiratory insufficiency:1||Coccidioidomycosis:1||Complications:1||Consensus:1||DLCO:1||Dactylitis:1||Diagnosis:1||Direct gene sequencing:1||Diseases progression:1||Docetaxel:1||Drug therapy:1||Durvalumab:1||EGER mutation:1||EGFR T790M:1||EGFR T790M mutation:1||EGFR&#8208:1||EGFRTKI therapy:1||EGFRtyrosine kinase inhibitor:1||ERCC1:1||Early diagnosis:1||Endoplasmic reticulum stress:1||ErbB receptors:1||Ethyl pyruvate:1||Exhaled breath condensate:1||Extensive stage disease:1||Extubation:1||FEV1:1||Factor XIII:1||Failure togefitinib:1||

STATISTICS: Total View :12,790,646; Today View :22,361

RSS_1.0 RSS_2.0 ATOM_1.0

73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE